Foundation directory

Foundation for Angelman Syndrome Therapeutics Grants

Public charity · Austin, TX · EIN 26-3160079

Foundation for Angelman Syndrome Therapeutics is a public charity in Austin, TX. Its grant programs below were checked against the funder's own website.

cureangelman.org · website as filed with the IRS

Research profile compiled by GrantCue from IRS records and the funder's own website. It is not the funder's own website, request for proposals or application page.

Looking for grants for your organization?

GrantCue lists Foundation for Angelman Syndrome Therapeutics's open programs and matches your organization to other grants and foundations that fit.

Find grants for my organization

Open now

Opportunities and giving programs published on Foundation for Angelman Syndrome Therapeutics's website. Confirm details with the foundation before applying.

Innovation Seed Grant

Open · closing date not stated

Checked against Foundation for Angelman Syndrome Therapeutics's website on October 30, 2026

Last full review: October 30, 2026

Supports innovative, high-risk, high-reward proof-of-concept research to advance understanding and treatment of Angelman syndrome (treatment strategies, therapeutic targets, biomarker identification). One-time awards that must be completed within a year of funding; grants range from $10,000 to $50,000.

Eligibility and rules

Eligible applicants

  • Institutions receiving grants are generally recognized as nonprofit organizations; in rare circumstances funding is given to contract research organizations or industry scientific teams.
  • Individuals should have training and experience at least equal to the Ph.D. or M.D. level.
  • Open to individual researchers, multidisciplinary research teams, and collaborative partnerships between academic institutions and industry entities.
  • Applicants must prepare a one-page Letter of Intent including hypotheses and specific aims, a lay summary, a detailed budget and a biosketch of the PI and collaborators.
  • No more than 20% of the funds requested can be used for salary and fringe benefits.
  • Indirect costs, general office supplies/equipment, and bridging funds to cover gaps in grant funding are not allowable.
  • FAST will not consider grant applications with essentially the same research focus from the same applicant organization, including derivative or multiple applications aiming to create a single product, process or service.
  • All proposed work must be completed within one year of funding, with a final report due within 60 days after the project termination date.
  • IRB approval is required prior to dispersal of funds if human subjects are used (award may be rescinded if not obtained within 6 months), and IACUC approval is required before any animal work.

Deadline

All grant applications have a rolling deadline.

Dates come from the foundation's own website. Check their page before applying.

Grants it reported

From its IRS Form 990, Schedule I, for tax year 2025. Only recipients that received more than $5,000 in the year are listed, and each amount is that year's total for the recipient.

13 recipients · $1.3M in cash grants

  • Form 990 doesn't say whether a funder accepts applications.
RecipientLocationPurposeCash
Boston Children's HospitalBoston, MAFt2022-006: abom - natural history study$363.3K
Center for Breakthrough Medicines LLCKing of Prussia, PAThe manufacturing (cdmo), personnel$164.2K
Fraunhofer UK Research Limited Technology & Innovation Centre—Ft2020-004 ext: banking dr. Yong-hui jiang's as ipscs with ebisc (services for the expansion, biobanking, and qc of 21 hips lines)$127.9K
Regents of the University of California DavisDavis, CAFt2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome$125.1K
Children's Research InstituteWashington, DCFt2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome$122.1K
The Regents of the University of California San FranciscoSan Francisco, CAFt2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome$111.3K
Yale UniversityNew Haven, CTFt2020-004 ext: banking dr. Yong-hui jiang's as ipscs with ebisc$90.1K
North Carolina State UniversityRaleigh, NCFt2022-008 ext: creation of stable infrastructure for testing of potential therapeutics for angelman syndrome in human stem-cell-derived models$55.8K
Keck Graduate Institute of Applied Life SciencesClaremont, CAFt2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides$40.1K
Research Triangle InstituteResearch Triangle Park, NCAbom: development of the angelman syndrome specific neurodevelopment training manual$31.9K
Fred Hutchinson Cancer CenterSeattle, WAIsg2025-002: hematopoietic stem cell mobilization, engineering, and engraftment without myeloablative conditioning$31.1K
Junipero TherapeuticsDurham, NCIsg2025-001: epigenome editing by induced proximity to durably restore paternal ube3a expression$29.2K
Yale UniversityNew Haven, CTFt2020-006 ext: generation and characterization of a new as mouse model that recapitulates the large deletion of human 15q11-q13 and a control line that carries a deletion of all genes in 15q11-q13 bu$10.4K

How to cite: GrantCue Foundation Directory, grantcue.com/foundations/foundation-for-angelman-syndrome-therapeutics-263160079